Vera Therapeutics Inc Class A VERA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VERA is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $36.84
- Day Range
- $36.19–37.96
- 52-Week Range
- $9.24–50.78
- Bid/Ask
- $36.62 / $40.00
- Market Cap
- $2.01 Bil
- Volume/Avg
- 444,747 / 715,586
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 55
- Website
- https://www.veratx.com
Comparables
Valuation
|
Metric
|
VERA
|
CTIC
|
BMEA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.67 | — | 1.47 |
Price/Sales | — | 14.71 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VERA
|
CTIC
|
BMEA
|
|---|---|---|---|
Quick Ratio | 27.87 | 1.20 | 5.74 |
Current Ratio | 28.63 | 1.27 | 5.84 |
Interest Coverage | −20.76 | −3.20 | — |
Quick Ratio
VERA
CTIC
BMEA
Profitability
|
Metric
|
VERA
|
CTIC
|
BMEA
|
|---|---|---|---|
Return on Assets (Normalized) | −35.75% | −46.52% | −58.31% |
Return on Equity (Normalized) | −47.90% | — | −68.60% |
Return on Invested Capital (Normalized) | −41.21% | −143.40% | −69.59% |
Return on Assets
VERA
CTIC
BMEA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Twmsbvzjw | Zccc | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ncbcfjd | Lddzjb | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Jrtkyvj | Prfcpc | $117.3 Bil | |||
| Moderna Inc
MRNA
| Kzjtlch | Ynbm | $46.1 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Plkrzmmx | Nsltcn | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Przdbbk | Vkjd | $28.8 Bil | |||
| BioNTech SE ADR
BNTX
| Dzlhplskc | Swzp | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Kvchptqf | Lmbkcz | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Bpkjjwyhh | Kvcgm | $14.9 Bil | |||
| Incyte Corp
INCY
| Dwtkdwdx | Ryvmfr | $13.5 Bil |